Patent · US Expired

Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides

US7083791B2 · kind B2 · utility

12Cited by
0References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 3, 2003
Grant dateAug 1, 2006
Priority date
Expiry dateDec 8, 2023

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Isolated fibroblast growth factor receptor (FGFR5) polypeptides and polynucleotides encoding such polypeptides are provided. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to and agonize or antagonize FGFR5 polypeptide function. Specific binding molecules include antibodies, functional fragments thereof, as well as scFv and Camelidae heavy chain IgG that specifically bind to FGFR5 thereby modulating the activity of FGFR5 and, thus, are effective agents suitable for the treatment of diseases such as osteopontin-mediated autoimmune disease, such as systemic lupus erythematosus, bone disorders including osteoporosis and osteopetrosis, and cancers, including cellular carcinomas such as hepatocellular carcinomas.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.